Methylation Markers for Urine-Based Detection of Bladder Cancer: The Next Generation of Urinary Markers for Diagnosis and Surveillance of Bladder Cancer

Table 1

Sensitivity and specificity of cytology, NMP22, ImmunoCyt, and UroVysion when no distinguishment is made between patients with suspicion of bladder cancer and patients previously diagnosed with bladder cancer.

Test	Samples/studies	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Interference by other bladder conditions	Comments	Reference
Cytology^a	14260/36	44 (38–51)	96 (94–98)	Yes	Subjective judgement	[12]
NMP22^b	10119/28	68 (62–74)	79 (74–84)	Yes	Cutoff was ≥10 U/mL for positive test result	[12]
ImmunoCyt	2896/8	84 (77–91)	75 (68–83)	Yes	At least one green or one red fluorescent cell	[12]
UroVysion	2535/12	76 (65–84)	85 (78–92)	No	Cutoffs may vary between studies	[12]

^a Voided urine only.
^b Including five studies using NMP22 BladderChek.